Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	REDA Gianluigi CASSIN Ramona DOVRTĚLOVÁ Gabriela MATTEO Cristina GIANNOTTA Juri D'INCALCI Maurizio CORTELEZZI Agostino ZUCCHETTI Massimo
Year of publication	2019
Type	Article in Periodical
Magazine / Source	Haematologica
MU Faculty or unit	Faculty of Medicine
Citation
Web	http://www.haematologica.org/content/early/2019/02/07/haematol.2018.213157.abstract
Doi	http://dx.doi.org/10.3324/haematol.2018.213157
Keywords	CNS involvement; Chronic Lymphocytic Leukemia; venetoclax
Description	Venetoclax, a selective inhibitor of BCL2, has shown promising efficacy in chronic lymphocytic leukemia (CLL) both as single agent or in combination therapy. Central nervous system involvement (CNSi) is a rare complication of CLL and is reported in approximately 0.4% of patients. Therapeutic guidelines have not yet been established and prognosis for these patients is poor. Few cases of CLL with CNSi have been reported until now, and ibrutinib was successfully used due to its ability to penetrate the blood-brain barrier.
Related projects:	CZECRIN - Český národní uzel Evropské sítě infrastruktur klinického výzkumu CZECRIN_PRO PACIENTY - zavádění inovativních moderních terapií